(redirected from Reteplase)
Also found in: Dictionary, Thesaurus, Medical, Financial, Encyclopedia, Wikipedia.
Related to Reteplase: Tenecteplase


A map of a town or a section of land that has been subdivided into lots showing the location and boundaries of individual parcels with the streets, alleys, easements, and rights of use over the land of another.

A plat is usually drawn to scale.

West's Encyclopedia of American Law, edition 2. Copyright 2008 The Gale Group, Inc. All rights reserved.

PLAT. A map of a piece of land, in which are marked the courses and distances of the different lines, and the quantity of land it contains.
     2. Such a plat;nay be given in evidence in ascertaining the position of the land, and what is included, and may serve to settle the figure of a survey, and correct mistakes. 5 Monr. 160. See 17 Mass. 211; 5 Greenl. 219; 7 Greenl, 61; 4 Wheat. 444; 14 Mass. 149.

A Law Dictionary, Adapted to the Constitution and Laws of the United States. By John Bouvier. Published 1856.
References in periodicals archive ?
While the mean age of male and female patients treated by reteplase was 56.6 [+ or -] 3.98 and 65.0 [+ or -] 3.59 years, respectively.
When eptifibatide was applied within 3 hours and reteplase + abciximab within 3 to 6 hours, neurological improvement was reported.
Keywords: Escherichia coli, Recombinant proteins, Reteplase, Tissue plasminogen activator
Until now, physicians did not know whether using all three treatments (reteplase, abciximab, and angioplasty) together would increase the risk of bleeding.
To overcome this problem, reteplase can be targeted to the periplasmic space which has less reducing environment as compared to cytoplasm (6).
Food and Drug Administration for acute ischemic stroke, recombinant TPA, such as alteplase and reteplase, are being used off label for intraarterial lysis in ischemic stroke.
In the STEMI study, 32 patients who received reteplase were randomized to receive infusions of insulin, dextrose, and potassium or normal saline and potassium for 48 hours.
Fibrinolytic agents include urokinase (Abbokinase[R]), tenecteplase (TNKase[R]), streptokinase (Streptase[R], Kabikinase[R]), alteplase (Cathflo[R], Activase[R], t-PA), reteplase (Retavase[R]), and anistreplase (Eminase[R], APSAC).
Enzymes that are currently in use for catheter clearance are streptokinase, alteplase, and reteplase (see Table 1).
That proposition is now undergoing definitive testing in the Early Reteplase Thrombolysis in Myocardial Infarction-19 (ER TIMI-19) trial.
(About 60% of patients received streptokinase, 27% received reteplase, and the remaining patients received other agents.) Patients with less than 50% resolution of their ST changes were randomized to one of three treatment strategies: conservative management in the hospital, repeat treatment with thrombolysis, or PCI (about 69% of the PCI-treated patients received coronary stents).
But the value of adding reviparin or a similar agent remains in doubt when patients are treated with the fibrin-specific drugs most often used for thrombolysis in the United States, such as alteplase (tissue plasminogen activator), reteplase, and tenecteplase.